DARNYTSIA
DEAD

Serial Number

79398507

Owner

PRIVATE JOINT STOCK COMPANY

Attorney

Michael G Shariff

Filing Date

Jan 8, 2024

Add to watchlist:

No watchlists yet
View on USPTO

DARNYTSIA Trademark

Serial Number: 79398507

DARNYTSIA is a trademark filed by PRIVATE JOINT STOCK COMPANY on January 8, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

PRIVATE JOINT STOCK COMPANY

vul. Heolohiv, 12A,

Entity Type: 99

Trademark Details

Filing Date

January 8, 2024

Registration Date

Not Registered

Goods & Services

Antiseptics; vaccines; veterinary preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vitamin preparations; disinfectants; diagnostic preparations for veterinary purposes; diagnostic preparations for medical purposes; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; plant extracts, other than essential oils, for pharmaceutical purposes; herbal extracts, other than essential oils, for medical purposes; capsules sold empty for pharmaceuticals; medicinal preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; drugs for medical purposes being pharmaceuticals for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medicinal drinks; medicinal oils, other than essential oils; medicated toiletry preparations; medicated shampoos; ointments for pharmaceutical purposes, namely, medicated ointments for treating dermatological conditions and antibiotic ointments; teeth filling material; medicinal alcohol; food supplements; medical dressings; nutritional supplements; syringes sold filled with pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; air purifying preparations; food for babies; protein dietary supplements; tissues impregnated with pharmaceutical lotions for treating dermatological conditions; alcohol for pharmaceutical purposes; stem cells for medical purposes; transplants, namely, surgical implants comprising living tissue used in transplant operations; pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; ferments for pharmaceutical purposes; phytotherapy preparations for medical purposes; chemico-pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; chemical preparations for medical purposes for the diagnosis of pregnancy; chemical preparations for pharmaceutical purposes for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; chemical reagents for medical or veterinary purposes; surgical glues; surgical dressings; medicated sweets; crystallized rock sugar for medical purposes; sanitary preparations for medical purposes; plasters for medical purposes

Health care public relations services, namely, promoting and marketing the goods and services of others in the health care industry through all public communication means; wholesale store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies; retail store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies; dissemination of advertising matter on communication media relating to health care goods, programs and services; marketing services in the nature of promoting health care goods, programs and services of others

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 5, 2026 OPNX
CORRECTION TRANSACTION RECEIVED FROM IB
Jan 1, 2026 CRCV
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 26, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Nov 26, 2025 OPNR
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jul 31, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jul 31, 2025 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 31, 2024 GNRN
NON-FINAL ACTION E-MAILED
Dec 31, 2024 GNRT
NON-FINAL ACTION WRITTEN
Dec 31, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 10, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 9, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 9, 2024 TROA
REFUSAL PROCESSED BY IB
Sep 9, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 19, 2024 RFCS
REFUSAL PROCESSED BY MPU
Aug 17, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 8, 2024 RFCR
NON-FINAL ACTION WRITTEN
Aug 7, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 2, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 24, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 24, 2024 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jul 23, 2024 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 27, 2024 REPR